Dry Eyes and Menopause: Labs, Causes, and Your Next Steps

Why Menopause Causes Dry Eyes: The Hormone Connection

Dry eye in menopause is not random and is not "just aging." Hormonal shifts directly impair two separate parts of the tear-producing system, and understanding which part is failing in your case changes what treatment will actually work.

Your tear film has three layers: an outer oily layer made by meibomian glands in your eyelids, a middle watery layer made by lacrimal glands, and an inner mucin layer produced by goblet cells on the eye surface. Menopause disrupts all three.

Androgens and the Meibomian Glands

The meibomian glands in your eyelids are androgen-dependent. They express androgen receptors, and testosterone and DHEA directly regulate how much lipid they secrete. Research published in Investigative Ophthalmology & Visual Science showed that androgen deficiency leads to meibomian gland dysfunction (MGD) and evaporative dry eye, the most common subtype in postmenopausal women. When androgens fall in perimenopause, the oil layer thins, tears evaporate too fast, and your eyes feel gritty, burning, or blurry within hours of waking.

Estrogen's Role in Goblet Cells and Tear Volume

Estrogen receptors line the conjunctival goblet cells that produce mucin, the sticky layer that helps tears adhere to your eye surface. Falling estradiol reduces goblet-cell density and mucin secretion. A 2019 review in Menopause confirmed that postmenopausal women have significantly lower conjunctival goblet-cell density compared with premenopausal women, contributing to aqueous-deficient and mixed-type dry eye.

Why Women Are Hit Harder Than Men

Sex-specific data matters here. Women account for approximately 59% of the 16.4 million adults diagnosed with dry eye disease in the United States. The Women's Health Study, which surveyed 25,665 women aged 45 to 84, found that women using hormone therapy (oral estrogen alone, without progestogen) had a 70% higher odds of dry eye compared with non-users. This is the counterintuitive finding most articles skip: oral estrogen without androgen support may worsen dry eye rather than fix it.

Diagnosing Dry Eyes in Menopause: Tests and Labs to Request

A diagnosis of menopausal dry eye is not made by symptoms alone. You deserve a structured evaluation, not a guess.

Eye-Specific Tests Your Optometrist or Ophthalmologist Should Run

Tear break-up time (TBUT): A drop of fluorescent dye is placed in your eye, and the examiner measures how long it takes for the tear film to develop dry spots after a complete blink. A TBUT below 10 seconds is abnormal. Evaporative dry eye from MGD typically produces a very short TBUT, often under 5 seconds.

Schirmer test: A small strip of paper is placed at the edge of your lower lid for 5 minutes. Less than 5 mm of wetting indicates aqueous-deficient dry eye. Values between 5 and 10 mm are borderline and warrant repeat testing with your symptoms in context.

Tear osmolarity: A tiny sample of tears is tested for salt concentration. Osmolarity above 308 mOsm/L or an intereye difference greater than 8 mOsm/L is diagnostic of dry eye disease. This test is highly reproducible and increasingly available in primary eyecare offices.

Meibography: Infrared imaging of your meibomian glands reveals dropout or truncation, the structural changes that confirm MGD. Ask specifically for this if your symptoms are worst in the morning or improve temporarily after blinking hard.

Corneal staining: Fluorescein and lissamine green dyes reveal surface damage. Staining patterns help grade severity and guide treatment urgency.

Blood Labs That Change the Picture

Dry eye at menopause sits at the intersection of endocrinology and ophthalmology. These labs help separate hormonal causes from autoimmune ones.

| Lab | What It Tells You | Normal Range (context) | |-----|-------------------|----------------------| | FSH | Confirms menopausal status | >30 IU/L postmenopause | | Estradiol (E2) | Quantifies estrogen deficiency | <30 pg/mL postmenopause | | Total testosterone | Androgen status at the gland level | 15 to 70 ng/dL in adult women | | Free testosterone | Biologically active androgen fraction | 0.3 to 1.9 ng/dL (age-dependent) | | DHEAS | Adrenal androgen precursor; falls with age | 35 to 430 mcg/dL (age 40 to 49) | | TSH | Thyroid dysfunction causes or worsens dry eye | 0.5 to 4.5 mIU/L | | ANA screen | Screens for autoimmune disease | Negative | | Anti-SSA (Ro), Anti-SSB (La) | Specific to Sjögren syndrome | Negative |

Sjögren syndrome deserves its own sentence. It affects roughly 4 million Americans, is nine times more common in women than men, and peaks in incidence around perimenopause, the exact window when many women attribute their dry eyes solely to hormones. A negative ANA and negative anti-SSA/SSB with a clear menopausal timeline are genuinely reassuring. A positive result means referral to rheumatology before you invest time in hormone-based therapies.

When to Ask for a Formal Menopause Evaluation Alongside Eye Care

If your eye symptoms appeared or worsened in the 2 to 5 years around your last menstrual period, especially alongside hot flashes, night sweats, or genitourinary symptoms, request a coordinated visit with a menopause-specialist clinician in addition to your eye doctor. Your dry eyes are a systemic symptom, not just an ocular one.

Treatment for Dry Eyes in Menopause: What the Evidence Actually Shows

Treatment works best when it matches the mechanism. Evaporative dry eye from MGD responds differently than aqueous-deficient dry eye from lacrimal gland insufficiency.

Step 1: Preservative-Free Artificial Tears

Start here regardless of subtype. The 2017 DEWS II (Dry Eye Workshop II) report, the most comprehensive clinical guideline on dry eye management, recommends preservative-free artificial tears as first-line therapy because preserved drops can worsen surface inflammation with frequent use. For menopausal women using drops four or more times daily, preservative-free unit-dose vials are the right choice, not the bottled multi-dose preserved options.

Formulations matter. Lipid-containing drops (e.g., Systane Complete, Soothe XP) address evaporative MGD better than plain carboxymethylcellulose drops. Sodium hyaluronate-based drops may be better tolerated for women with conjunctival sensitivity.

Step 2: Meibomian Gland Dysfunction Treatments

If meibography confirms gland dysfunction or TBUT is consistently below 5 seconds, add:

Warm compresses: At least 10 minutes daily at 40°C to 45°C (a warm, not hot, compress) softens the stagnant meibum. A randomized trial published in Ophthalmology showed significant TBUT improvement after 2 weeks of daily warm compresses in MGD patients.

Omega-3 fatty acids: The DREAM trial (published in NEJM 2018) found omega-3 supplementation (3,000 mg EPA+DHA daily) did not outperform olive oil placebo for dry eye symptoms scores at 12 months, which was a genuinely humbling result for this previously popular recommendation. Omega-3s remain low-risk and may modestly help tear film quality in subgroups, but set expectations appropriately.

In-office thermal pulsation (LipiFlow): A single 12-minute in-office treatment applies heat and pressure to express the meibomian glands. A multicenter trial showed significant improvement in TBUT and meibomian gland secretion scores at 3 months versus warm compresses alone. Cost is a real barrier (approximately $700 to $1,200 out of pocket); it is not standard first-line care.

Step 3: Prescription Anti-Inflammatory Drops

Chronic dry eye triggers a vicious cycle of ocular surface inflammation that perpetuates gland damage. Two prescription options have FDA approval.

Cyclosporine 0.05% (Restasis) and 0.09% (Cequa): Cyclosporine suppresses T-cell mediated inflammation on the ocular surface. The key Phase III trials for Restasis showed a significant increase in Schirmer test wetting and reduction in corneal staining versus vehicle at 6 months. Effects take 3 to 6 months to peak, which is the most common reason women stop too early.

Lifitegrast 5% (Xiidra): A lymphocyte function-associated antigen-1 (LFA-1) antagonist approved by the FDA in 2016. Four randomized controlled trials showed significant reduction in eye dryness score versus placebo at 12 weeks. Some women notice a temporary dysgeusia (altered taste) through the nasolacrimal duct. Symptom relief with lifitegrast tends to come faster than with cyclosporine.

Step 4: Systemic Hormone Therapy and the Evidence Problem

This is where most women expect the simple answer: replace estrogen, fix your eyes. The evidence refuses to cooperate.

The Women's Health Study found that women on oral estrogen-alone therapy had a 69% increased risk of dry eye diagnosis versus non-users. Women on combined estrogen-progestogen therapy had a 29% increased risk. These are observational data and cannot prove causation, but the signal is consistent enough that recommending systemic HRT specifically to treat dry eye is not evidence-based. HRT may still be appropriate for hot flashes, bone protection, or genitourinary symptoms, but do not expect it to rescue your tear film.

Topical androgen drops (0.03% testosterone ophthalmic drops) have shown early promise in small trials. A pilot study in Cornea found improved Schirmer scores in androgen-deficient postmenopausal women treated with topical testosterone drops compared with placebo. These are not FDA-approved, require compounding pharmacy preparation, and should be considered only at a center with expertise in ocular surface disease.

Step 5: Punctal Plugs and Advanced Options

If steps 1 through 3 provide inadequate relief at 3 months, referral to a cornea specialist is appropriate. Punctal plugs (small silicone inserts that slow tear drainage) are reversible, office-based, and often dramatically effective for aqueous-deficient dry eye confirmed by a low Schirmer score. A Cochrane review found punctal plug insertion improved symptoms and objective dry eye signs compared with lubricant drops alone.

Dry Eyes Across the Female Life Stages

Dry eye does not start and stop at menopause. Knowing which life stage you are in shapes which symptoms to report and which tests are most relevant.

Reproductive Years (Ages 20 to 40)

Dry eye in this group is most often linked to contact lens wear, low androgen states (PCOS-related hyperinsulinemia paradoxically lowers free androgen availability at tissue level), and extended screen time. Oral contraceptive use has been associated with reduced tear volume in some studies, likely via suppressed androgen production from combined estrogen-progestogen pills. A study in Contact Lens and Anterior Eye found significantly shorter TBUT in OCP users compared with non-users.

Trying to Conceive and Pregnancy

Tear film changes during pregnancy are variable. Some women experience improvement (higher progesterone and estrogen may transiently support goblet cells); others worsen, especially in the third trimester. Dry eye symptoms in pregnancy should be managed with preservative-free artificial tears, which carry no known fetal risk. Cyclosporine eye drops have minimal systemic absorption when applied topically and are classified as FDA Pregnancy Category C; the risk-benefit decision should involve your OB.

Postpartum and Breastfeeding

Prolactin-dominant, estrogen-suppressed physiology during lactation can trigger or worsen dry eye, particularly in women who breastfeed for longer than 6 months. Preservative-free artificial tears are safe during breastfeeding. Restasis and Xiidra have negligible systemic absorption from topical use, making lactation exposure extremely low, but formal lactation safety data in humans are limited. Discuss with your provider before use.

Perimenopause (Ages 42 to 52, Variable)

This is the highest-risk window for new-onset symptomatic dry eye. FSH begins rising while estradiol fluctuates; androgens are in sustained decline. Screen actively at annual well-woman visits. Request TBUT and Schirmer testing if symptoms are present.

Post-Menopause (Ages 52+)

Risk is cumulative. By age 65, prevalence of clinically significant dry eye in women approaches 30 to 34%. The differential at this stage must include thyroid dysfunction (TSH), Sjögren syndrome (anti-SSA/SSB), and medication side effects (antihistamines, antidepressants, diuretics, and beta-blockers all reduce tear production).

When to Worry: Red-Flag Symptoms That Need Urgent Evaluation

Most menopausal dry eye is uncomfortable, not dangerous. These symptoms are different and warrant same-week or same-day eye care.

• Sudden change in vision not resolved by blinking
• Eye pain that is sharp, not just gritty irritation
• Redness concentrated around the cornea (limbal injection)
• Photophobia that comes on acutely
• Visible discharge (suggests infection, not dry eye)
• Dry eye plus dry mouth plus joint pain (the classic Sjögren triad)

DEWS II grading criteria classify dry eye as severe when it includes corneal ulceration or scarring. That stage requires urgent specialist care, not more lubricant drops.

Conditions That Overlap With Menopausal Dry Eye

Several conditions share the same demographic and the same symptom profile, and missing them delays real treatment.

Sjögren syndrome peaks around menopause. The American College of Rheumatology criteria require positive anti-SSA antibodies or a positive lip biopsy plus abnormal eye staining score or Schirmer <5 mm.

Hypothyroidism reduces lacrimal gland secretion directly. A TSH above 4.5 mIU/L in a woman with dry eye symptoms warrants a full thyroid panel; postpartum thyroiditis affects up to 10% of women in the first year after delivery and is another overlooked dry-eye trigger.

Rosacea (ocular subtype) affects the meibomian glands in the same way MGD does and is more common in perimenopausal women. Look for facial flushing, telangiectasias, or a history of rosacea.

Androgen insensitivity or low DHEAS in women with premature ovarian insufficiency (POI) mirrors the menopausal androgen picture and should be evaluated with DHEAS and free testosterone.

Your Practical Next Steps: What to Do This Week

If you have arrived at this article because your eyes have been scratchy, burning, or blurring for weeks or months, here is a concrete sequence.

1. Book two appointments simultaneously: one with an optometrist or ophthalmologist who performs tear osmolarity and meibography, and one with a menopause-specialist clinician or your OB-GYN.

2. Request these labs at your clinician visit: FSH, estradiol, total testosterone, DHEAS, TSH, ANA, and anti-SSA/SSB antibodies.

3. Start preservative-free lubricating drops today. Use them four to six times a day consistently for 4 weeks before assessing response. Lipid-based formulations are worth trying first if symptoms are worst on waking or in low-humidity environments.

4. Begin warm compresses nightly for 10 minutes if TBUT is below 10 seconds or meibography shows gland truncation.

5. Track your symptom pattern. The OSDI (Ocular Surface Disease Index), a 12-question validated questionnaire, takes under 2 minutes. Scores of 13 or above indicate at least mild dry eye disease. Bring your OSDI score to your eye appointment.

6. Do not wait a year. Women in the Beaver Dam Eye Study who had untreated dry eye for more than 5 years had significantly higher rates of corneal epithelial damage. Early treatment preserves the surface.

"Menopausal dry eye is a multi-system problem," says Rachel Goldberg, MD, member of the WomanRx clinical editorial board. "The women who do best are the ones who get their eyes tested objectively, not just reassured, and who work with both their eye doctor and their menopause clinician at the same time. Treating the eye in isolation misses half the picture."

The OSDI score cutoff of 23 or above indicates moderate-to-severe disease and is the threshold at which most cornea specialists initiate prescription therapy rather than continuing lubricants alone. If you score in that range, ask directly for a cyclosporine or lifitegrast trial.